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Introduction
Serum immunoglobulin levels play a significant role in the 
body’s defense against pathogens. There are five classes of 
immunoglobulins: immunoglobulin A (IgA), immunoglobu-
lin G (IgG), immunoglobulin M (IgM), immunoglobulin D 
(IgD) and immunoglobulin E (IgE). Immunoglobulin con-
centrations tend to increase with age1 or exposure to patho-
gens (antigens).2 Studies have also reported changes in 
serum immunoglobulin levels among subjects with type 2 
diabetes.1,3–4 Pro-inflammatory cytokine, interleukin 6 (IL-
6), plays an important role in the mediation of inflammatory 
response5–8 and is also involved in the development and 
acceleration of microvascular complications in patients 
with diabetes mellitus.9 The extent to which these circulat-
ing immunoglobulins influence metabolic dysfunction is 
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Objectives: Elevated immunoglobulin levels have been strongly linked to the development and progression of inflammatory 
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p = 0.001). There were positive correlations within the control group for immunoglobulin A versus interleukin 6 (r = 0.366, 
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Conclusion: Our data suggest that humoral immune response is altered in subjects with type 2 diabetes and that serum 
immunoglobulin levels could serve as useful biomarkers in the investigation and management of diabetes mellitus.
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not fully known particularly with regard to ethnicity. The 
purpose of this study was primarily to investigate possible 
immunological alterations associated with persons with 
type 2 diabetes and to identify which other factors influ-
ence humoral immune response in Ghanaian subjects with 
and/or without type 2 diabetes.
Methods
Study site, design, participants and exclusion 
criteria
This was a comparative cross-sectional study. Participants 
included 80 persons with type 2 diabetes, attending the 
National Diabetes Management and Research Center 
(NDMRC), Korle-Bu, Accra, and 78 age- and gender-
matched staff/workers of the Korle-Bu Teaching Hospital, 
Accra, Ghana, without diabetes mellitus. An oral glucose tol-
erance test (OGTT), regarded as diagnostic screening for 
type 2 diabetes, was performed on all volunteers. 
Anthropometric measurements such as height and weight 
were taken and body mass index (BMI) was calculated. 
Blood pressure was taken using a mercury sphygmomanom-
eter and stethoscope after participants had rested for 15 min. 
Type 2 diabetes was confirmed at the center (NDMRC) 
based on results of fasting blood glucose (FBG) ≤ 6.9 mmol/L 
and a 2-hr OGTT > 11.1 mmol/L on two separate occasions. 
Type 2 diabetic persons were either being lifestyle managed 
or were on oral hypoglycemic drugs. A pre-tested structured 
questionnaire was administered to assess the socio-economic 
status, medical history, medications and level of physical 
activity of subjects. The study was approved (Protocol 
Identification Number: MS-Et/M.2–P4.9/2013-2014) by the 
Institutional Ethics and Protocol Review Committee of the 
School of Medicine and Dentistry, College of Health 
Sciences, University of Ghana. Detailed explanations on 
purpose of the study, risk and benefits were made known to 
participants. Written informed consent was obtained from all 
participants. Subjects who have been smoking and drinking 
alcohol continuously for 6 months were excluded from the 
study. Subjects who were immunosuppressed such as those 
with immunoglobulin deficiency syndrome, HIV and hepati-
tis B were also excluded from the study. Participants who 
tested positive for the urine nitrite test or had bacterial and 
parasitic infections were also excluded from the study. The 
above have been proven to affect immunoglobulin levels in 
subjects.10 For minimum sample size determination, we 
established that 130 persons (65 persons for each study 
group) was adequate for this study, using a 6.3% prevalence 
rate for diabetes mellitus in Ghana,11 at 95% confidence 
interval and assuming a marginal error of 6%.
Laboratory procedure
Venous blood (9 mL) was obtained from the subjects between 
7 and 9 a.m. each day, after an overnight fast, according to 
Helsinki protocol declaration (2008). Two milliliters of 
whole blood was transferred into sodium fluoride containing 
tube and the plasma separated for the estimation of glucose. 
Three milliliters of whole blood was further transferred into 
ethylenediaminetetraacetic acid (EDTA) containing tubes 
for the estimation of glycated hemoglobin (HbA1c). The 
remaining 4 mL of whole blood was further processed, and 
resulting sera were then aliquoted in 1 mL portions into ster-
ile Eppendorf Tubes and stored at −20°C until analyzed.
Early morning spot urine samples from study subjects 
were collected into sterile plastic universal urine containers 
for urinalysis. FBG, total cholesterol (TC), triglycerides 
(TG), low-density lipoprotein (LDL) and high-density lipo-
protein (HDL) cholesterols were analyzed using the VITROS 
system chemistry auto-analyzer (version 250) (Ortho Clinical 
Diagnostics [version 5, 1 FS], Rochester, New Jersey, USA). 
HbA1c determination was based on a latex agglutination 
inhibition assay (Randox Laboratories Ltd, Kearneysville, 
WV, USA). The human IgA, IgG and IgM enzyme-linked 
immunosorbent assay (ELISA) Kits (USCN Life Science 
Inc., Wuhan, China) were used for in-vitro quantitative meas-
urement. IL-6 was analyzed using a kit purchased from 
Kamiya Biomedical Company, Tukwila, WA, USA. Specific 
secondary antibodies were used to eliminate unspecific bind-
ing to substrates. Calibration curves were used to determine 
analyte concentrations from the strength of signal produced 
by each immunoassay.
Statistical analysis
The Statistical Package for Social Sciences (SPSS) version 
20.0 (SPSS Software, San Diego, CA, USA) was used for 
analysis with level of statistical significance set at p < 0.05 
for all tests. Values are expressed as mean plus or minus 
standard deviations and also as medians with ranges where 
appropriate The Wilcoxon ranked sum testing was used to 
assess immunoglobulin and IL-6 levels in the study popula-
tion. The unpaired Student’s t-test was used to evaluate dif-
ferences between two means. Pearson product moment 
correlation coefficient (r) was used to find the association 
between two continuous variables.
Results
The clinical and biochemical parameters of the study popula-
tion are shown in Table 1. Eighty persons with type 2 diabe-
tes were age-matched with 78 non-diabetic controls. BMI, 
waist circumference (WC), HbA1c and FBG between the 
two study groups were statistically significant (p < 0.05). 
Comparison between the two study groups did not reveal any 
difference (p > 0.05) for systolic blood pressure (SBP), dias-
tolic blood pressure (DBP), TC, TG, HDL and albumin. The 
median IgA, IgG and IL-6 concentrations were significantly 
higher (p < 0.05) in persons with type 2 diabetes compared 
with controls. Median values for IgM, between the two study 
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groups, were not statistically significant (p = 0.270) (Table 
1). Associations between several parameters (age, BMI, 
SBP, FBG, HbA1c, LDL and HDL) with IgA, IgG, IgM and 
IL-6 have been shown in Table 2. There were negative asso-
ciations for HbA1c versus IgG (r = −0.220, p = 0.013) and 
positive correlation for BMI versus IgG (r = 0.161, p = 0.043), 
FBG versus IgA (r = 0.170, p = 0.031), FBG versus IgG 
(r = 0.252, p = 0.001), HbA1c versus IL-6 (r = 0.190, 
p = 0.020), IL-6 versus IgA (r = 0.326, p = 0.002) and IL-6 
versus IgM (r = 0.177, p = 0.031), respectively, within the 
case group. Control group had a negative relationship for 
HbA1c versus IgG (r = −0.281, p = 0.012) and a positive 
association for IL-6 versus IgA (r = 0.366, p = 0.001).
Discussion
This study sought to investigate serum levels of immuno-
globulins (IgA, IgG and IgM) and IL-6 in Ghanaian persons 
with type 2 diabetes. Even though the distribution of the 
three immunoglobulins did not follow normal distribution 
and was skewed, the ranges for immunoglobulin levels 
measured for persons without type 2 diabetes in this study 
were consistent with established ranges12 for healthy indi-
viduals. Results from this study generally did not agree with 
previous findings.1,4 Our data showed that concentration of 
IgG was greater than the other immunoglobulins (IgA and 
IgM) in both persons with and without type 2 diabetes, 
confirming primarily the existing information that IgG is the 
most abundant circulating immunoglobulin in humans.2 
Again, the observed significantly higher IgG concentrations 
among subjects with type 2 diabetes compared with their 
control counterparts could be a result of chronic metabolic 
dysfunction with accompanying low-grade inflammation.13
Concentrations of IgA in this study were significantly 
higher in the case cohort. This observation may reflect the 
possible accumulation of inflammatory conditions associ-
ated with type 2 diabetes.1 Furthermore, IgA is reported to 
be a non-specific marker in the development of diabetic 
complications.4 IgA levels also associated significantly 
with serum concentrations of IL-6, a marker of inflamma-
tion and a co-factor for immunoglobulin synthesis.1 
Therefore, monitoring IgA may provide early warning of 
possible presence of complications. Serum IgM levels in 
this study were not different in both study groups and was 
consistent with prior studies.1,3 Serum IL-6 levels were 
significantly higher in subjects with type 2 diabetes than 
their non-diabetic counterparts. This finding agreed with 
earlier observations,14,15 but contradicted another study.16 
It has been reported that elevated levels of IL-6 indepen-
dently increases the risk of developing type 2 diabetes by 
diminishing insulin sensitivity.6,17 This study, however, 
was unable to measure the insulin resistant state of partici-
pants. IL-6 has also been implicated in the development 
and acceleration of microvascular complications in 
Table 1. Clinical and biochemical parameters of study population.
Parameters Type 2 diabetes (N = 80) Controls (N = 78) p-value
Age (years) 50.6 ± 7.4 48.1 ± 7.1 0.061
M/F 38/42 38/40 –
BMI (kg/m2) 29.7 ± 5.8 25.1 ± 4.1 0.001
WC (cm) 99.7 ± 15.2 88.5 ± 11.4 0.001
SBP (mm Hg) 137.8 ± 17.2 132 ± 19.8 0.080
DBP (mm Hg) 82.7 ± 10.1 78.8 ± 19.2 0.112
FBG (mmol/L) 8.7 ± 3.7 4.3 ± 0.7 0.001
HbA1c (%) 7.2 ± 1.3 5.6 ± 0.9 0.019
TC (mmol/L) 5.0 ± 1.4 5.2 ± 1.1 0.184
TG (mmol/L) 1.2 ± 0.6 1.2 ± 0.9 0.983
HDL (mmol/L) 1.3 ± 0.5 1.3 ± 0.3 0.467
LDL (mmol/L) 3.1 ± 1.3 3.3 ± 0.9 0.156
T. protein (g/L) 76.2 ± 8.1 79.1 ± 4.8 0.007
Albumin (g/L) 44.0 ± 3.9 46.5 ± 4.2 0.188
Period of diabetes (years) 8.6 ± 5.4 – –
IgA (g/L) 0.89 (0.36−4.81) 0.74 (0.34−3.51) 0.043
IgG (g/L) 7.59 (6.43−8.35) 7.29 (4.68−11.65) 0.001
IgM (g/L) 0.73 (0.08−4.99) 0.57 (0.01−4.06) 0.263
IL-6 (pg/mL) 1.70 (0.39−14.93) 0.99 (0.01−4.52) 0.001
M: male; F: female; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; HbA1c: glycated hemoglobin; TC: total 
cholesterol; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein; BMI: body mass index; T. protein: total protein; WC: waist 
circumference; IL: interleukin; IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M.
Values are given as mean ± standard deviation and also as medians with minimum–maximum ranges (within parenthesis). Mean difference is significant 
(p < 0.05). Bolded results indicate significant relationships.
p < 0.05 is statistically significant.
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patients with diabetes mellitus.9 HbA1c and FBG in this 
study were higher in persons with type 2 diabetes com-
pared with the control group and positively correlated 
with IL-6 suggesting an inflammatory crosstalk in glucose 
regulation.18,19 SBP and DBP in this study, were not differ-
ent between the two study groups. According to Amoah 
et al.,20 chronic glycemic status tended to be associated 
with increase in SBP and DBP. Persons with type 2 diabe-
tes in this study were, however, on prescribed medication 
and such management practice could have been responsi-
ble for such observation. BMI and WC in this study were 
found to be significantly higher in the case group com-
pared to controls. High BMI and WC are markers of adi-
posity and have the potential for the development and 
progression of type 2 diabetes.21–25
This study had some limitations. Although the authors pri-
marily focused on overweight subjects, a normal weight con-
trol group would have been useful in a cross-sectional 
comparison manner. Another limitation was our inability to 
measure the insulin resistant state of our subjects. Furthermore, 
the authors did not have complete information regarding type 2 
diabetic complications. Future studies should focus on large 
population-based longitudinal studies to understand the mecha-
nistic role of immunoglobulins and inflammatory markers in 
insulin resistance and other metabolic disorders. In conclusion, 
circulating immunoglobulin levels could serve as useful bio-
markers in the investigation and management of diabetes mel-
litus. Implications of humoral responses in diabetes mellitus 
merit further investigation.
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